ReviewExperimental hematology & oncology2018
Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine.
Review in Experimental hematology & oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
95 citing papers in PubMed, 184 citations in OpenAlex.
- Real-time sensing-integrated organoid-on-a-chip platforms: Technological progress and emerging biomedical applications.Bioactive materials · 2026Review
- Phthalate Metabolite, Mono(2-Ethyl-5-Hydroxyhexyl) Phthalate (MEHHP), Promotes Uterine-Fibroid-Associated Phenotypes in Myometrial Stem Cell-Derived 3D Organoids.Environmental toxicology · 2026Article
- Human iPSC-Derived Brain Organoids: A Disease-Oriented Evaluation of Modeling Fidelity.The European journal of neuroscience · 2026Review
- KiGEP: a quantitative algorithm for calculating human kidney similarity and nephrotoxicity in human kidney organoids.Experimental & molecular medicine · 2026Article
- [Multi-omics integration deciphers immune-metabolic heterogeneity in colorectal cancer: a prognostic model and therapeutic strategies targeting ANGPTL4/FABP4/RBP7].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- The advancements in organoids: Potential and challenges in researching the esophagus and esophageal squamous cell carcinoma.Genes & diseases · 2026Review
- Bioactive hydrogels for the reconstruction of sensorineural hearing loss.Bioactive materials · 2026Review
- Tissue regenerative medicine: Clinical advances, challenges, and opportunities.APL bioengineering · 2025Article
- Rebuilding the MarrowOnco · 2025Article
- Regenerative reconstruction of mature esophageal epithelium by engraftment of esophageal organoids in de-epithelialized mouse colon.Pediatric surgery international · 2025Article
- Preclinical research in obesity-associated metabolic diseases using in vitro, multicellular, and non-mammalian models.Journal of physiology and biochemistry · 2025Review
- Human Nervous System-Based Biohybrid Robot-On-A-Chip with Sensing Function for Toxicity Screening.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Synovial organoids: From fundamental construction to groundbreaking applications in arthritic disorders.Journal of orthopaedic translation · 2025Review
- The Role of Organoids in Advancing Colorectal Cancer Research: Insights and Future Directions.Cancers · 2025Review
- Organoids in Haematologic Research: Advances and Future Directions.Cell proliferation · 2025Review
- Advanced Animal Replacement Testing Strategies Using Stem Cell and Organoids.International journal of stem cells · 2025Review
- Engineering bone/cartilage organoids: strategy, progress, and application.Bone research · 2024Review
- Modeling Epithelial Homeostasis and Perturbation in Three-Dimensional Human Esophageal Organoids.Biomolecules · 2024Article
- Ameliorating and refining islet organoids to illuminate treatment and pathogenesis of diabetes mellitus.Stem cell research & therapy · 2024Review
- Osteochondral organoids: current advances, applications, and upcoming challenges.Stem cell research & therapy · 2024Review
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Organoid technology bridges the gap between conventional two-dimensional cell line culture and in vivo models. The near-physiological technology can virtually recapitulates organ development and human diseases, such as infectious diseases, genetic abnormality and even cancers. In addition, organoids can more accurately predict drug responses, and serve as an excellent platform for drug development, including efficacy evaluation, toxicity testing and pharmacokinetics analysis. Furthermore, organoids can also be exploited to explore the possible optimized treatment strategies for each individual patient. Besides, organoid technology is a promising strategy for regeneration medicine and transplantation use, which can overcome the deficiency in the supply of healthy donor tissues and inherent immunological rejection through establishing isogenic organoids from minuscule amounts of patient biopsies. Collectively, organoids hold enormous potential for clinical applications and bring basic research closer to clinical practice. In this review, we described common organoid lines, summarized the potential clinical applications, and outlined the current limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.